A comparison of the pharmacological modulation of hyperalgesia and bronchial hyperresponsiveness

Pulmonary Pharmacology and Therapeutics

Volumn 16, Issue 1, 2003, Pages 31-44

  Spina, D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Asthma; Bronchial hyperresponsiveness; Capsaicin; Hyperalgesia; Nedocromil; NMDA; Non steroidal anti inflammatory drugs; Opioids; Vanilloid

Indexed keywords

443C81; ACETYLSALICYLIC ACID; ALFENTANIL; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIALLERGIC AGENT; CAPSAICIN; CLOBESTEROL; CLONIDINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DEXAMETHASONE; DEXTROMETHORPHAN; ENKEPHALIN DERIVATIVE; GLUCOCORTICOID; IBUPROFEN; KETAMINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIDOCAINE; LOCAL ANESTHETIC AGENT; MEXILITINE; MUSCARINIC RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEDOCROMIL SODIUM; NEUROKININ 1 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE AGONIST; PROSTAGLANDIN E2; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAFIRLUKAST;

ASTHMA; BRONCHUS HYPERREACTIVITY; CARDIOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG PENETRATION; DRUG TARGETING; HUMAN; HYPERALGESIA; MEDIATOR RELEASE; NEUROPATHIC PAIN; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SENSITIZATION; SENSORY NERVE; SENSORY NERVE CONDUCTION; SIDE EFFECT; SYSTEMIC THERAPY; TREATMENT FAILURE;

EID: 0037299047     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1094-5539(02)00173-6     Document Type: Article

References (204)

1. Spina D., Page C.P. Airway sensory nerves in asthma - targets for therapy? Pulm Pharmacol. 9:1996;1-18.
2. Van Schoor J., Joos G.F., Pauwels R.A. Indirect bronchial hyperresponsiveness in asthma: mechanisms, pharmacology and implications for clinical research. Eur Respir J. 16:2000;514-533.
3. Avital A., Springer C., Bar-Yishay E., Godfrey S. Adenosine, methacholine, and exercise challenges in children with asthma or paediatric chronic obstructive pulmonary disease. Thorax. 50:1995;511-516.
4. Spina D., Page C.P. Asthma - a need for a rethink? Trends Pharmacol Sci. 23:2002;311-315.
5. Julius D., Basbaum A.I. Molecular mechanisms of nociception. Nature. 413:2001;203-210.
6. Adcock J.J., Garland L.G. The contribution of sensory reflexes an 'hyperalgesia' to airway hyperresponsiveness. Page C.P., Gardner P.J. Airway hyperresponsiveness: is it really important for asthma. 1993;234-255 Blackwell Scientific, Oxford.
7. Woolf C.J., Mannion R.J. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet. 353:1999;1959-1964.
8. Dray A., Urban L., Dickenson A. Pharmacology of chronic pain. Trends Pharmacol Sci. 15:1994;190-197.
9. Baron R. Peripheral neuropathic pain: from mechanisms to symptoms. Clin J Pain. 16:2000;S12-S20.
10. MacPherson R.D. The pharmacological basis of contemporary pain management. Pharmacol Ther. 88:2000;163-185.
11. Sindrup S.H., Jensen T.S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 83:1999;389-400.
12. Botting R.M. Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin Infect Dis. 31:(Suppl 5):2000;S202-S210.
13. Narumiya S., Sugimoto Y., Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 79:1999;1193-1226.
14. Murata T., Ushikubi F., Matsuoka T., Hirata M., Yamasaki A., Sugimoto Y., Ichikawa A., Aze Y., Tanaka T., Yoshida N., Ueno A., Oh-ishi S., Narumiya S. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature. 388:1997;678-682.
15. Stock J.L., Shinjo K., Burkhardt J., Roach M., Taniguchi K., Ishikawa T., Kim H.S., Flannery P.J., Coffman T.M., McNeish J.D., Audoly L.P. The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure. J Clin Invest. 107:2001;325-331.
16. Southall M.D., Vasko M.R. Prostaglandin receptor subtypes, EP3C and EP4, mediate the prostaglandin E2-induced cAMP production and sensitization of sensory neurons. J Biol Chem. 276:2001;16083-16091.
17. Minami T., Nakano H., Kobayashi T., Sugimoto Y., Ushikubi F., Ichikawa A., Narumiya S., Ito S. Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice. Br J Pharmacol. 133:2001;438-444.
18. Kilo S., Forster C., Geisslinger G., Brune K., Handwerker H.O. Inflammatory models of cutaneous hyperalgesia are sensitive to effects of ibuprofen in man. Pain. 62:1995;187-193.
19. Bickel A., Dorfs S., Schmelz M., Forster C., Uhl W., Handwerker H.O. Effects of antihyperalgesic drugs on experimentally induced hyperalgesia in man. Pain. 76:1998;317-325.
20. Steen K.H., Reeh P.W., Kreysel H.W. Topical acetylsalicylic, salicylic acid and indomethacin suppress pain from experimental tissue acidosis in human skin. Pain. 62:1995;339-347.
21. Schmelz M., Kress M. Topical acetylsalicylate attenuates capsaicin induced pain, flare and allodynia but not thermal hyperalgesia. Neurosci Lett. 214:1996;72-74.
22. Petersen K.L., Brennum J., Dahl J.B. Experimental evaluation of the analgesic effect of ibuprofen on primary and secondary hyperalgesia. Pain. 70:1997;167-174.
23. Voilley N., de Weille J., Mamet J., Lazdunski M. Nonsteroid anti-inflammatory drugs inhibit both the activity and the inflammation-induced expression of acid-sensing ion channels in nociceptors. J Neurosci. 21:2001;8026-8033.
24. Koppert W., Dern S.K., Sittl R., Albrecht S., Schuttler J., Schmelz M. A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil. S(+)-ketamine, and lidocaine. Anesthesiology. 95:2001;395-402.
25. Petersen K.L., Jones B., Segredo V., Dahl J.B., Rowbotham M.C. Effect of remifentanil on pain and secondary hyperalgesia associated with the heat - capsaicin sensitization model in healthy volunteers. Anesthesiology. 94:2001;15-20.
26. Warncke T., Stubhaug A., Jorum E. Preinjury treatment with morphine or ketamine inhibits the development of experimentally induced secondary hyperalgesia in man. Pain. 86:2000;293-303.
27. Koppert W., Zeck S., Blunk J.A., Schmelz M., Likar R., Sittl R. The effects of intradermal fentanyl and ketamine on capsaicin-induced secondary hyperalgesia and flare reaction. Anesth Analg. 89:1999;1521-1527.
28. Park K.M., Max M.B., Robinovitz E., Gracely R.H., Bennett G.J. Effects of intravenous ketamine, alfentanil, or placebo on pain, pinprick hyperalgesia, and allodynia produced by intradermal capsaicin in human subjects. Pain. 63:1995;163-172.
29. Leung A., Wallace M.S., Ridgeway B., Yaksh T. Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 91:2001;177-187.
30. Lilleso J., Hammer N.A., Pedersen J.L., Kehlet H. Effect of peripheral morphine in a human model of acute inflammatory pain. Br J Anaesth. 85:2000;228-232.
31. LaMotte R.H., Shain C.N., Simone D.A., Tsai E.F. Neurogenic hyperalgesia: psychophysical studies of underlying mechanisms. J Neurophysiol. 66:1991;190-211.
32. Gottrup H., Bach F.W., Arendt-Nielsen L., Jensen T.S. Peripheral lidocaine but not ketamine inhibits capsaicin-induced hyperalgesia in humans. Br J Anaesth. 85:2000;520-528.
33. Gottrup H., Hansen P.O., Arendt-Nielsen L., Jensen T.S. Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans. Br J Anaesth. 84:2000;155-162.
34. Dahl J.B., Brennum J., Arendt-Nielsen L., Jensen T.S., Kehlet H. The effect of pre- versus postinjury infiltration with lidocaine on thermal and mechanical hyperalgesia after heat injury to the skin. Pain. 53:1993;43-51.
35. Warncke T., Stubhaug A., Jorum E. Ketamine, an NMDA receptor antagonist, suppresses spatial and temporal properties of burn-induced secondary hyperalgesia in man: a double-blind, cross-over comparison with morphine and placebo. Pain. 72:1997;99-106.
36. Weinbroum A.A., Gorodezky A., Niv D., Ben Abraham R., Rudick V., Szold A. Dextromethorphan attenuation of postoperative pain and primary and secondary thermal hyperalgesia. Can J Anaesth. 48:2001;167-174.
37. Pedersen J.L., Galle T.S., Kehlet H. Peripheral analgesic effects of ketamine in acute inflammatory pain. Anesthesiology. 89:1998;58-66.
38. Woolf C.J., Mannion R.J., Neumann S. Null mutations lacking substance: elucidating pain mechanisms by genetic pharmacology. Neuron. 20:1998;1063-1066.
39. Rupniak N.M., Kramer M.S. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci. 20:1999;485-490.
40. Hill R. NK1 (substance P) receptor antagonists - why are they not analgesic in humans? Trends Pharmacol Sci. 21:2000;244-246.
41. Campbell E.A., Gentry C., Patel S., Kidd B., Cruwys S., Fox A.J., Urban L. Oral anti-hyperalgesic and anti-inflammatory activity of NK(1) receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig. Pain. 87:2000;253-263.
42. Laird J.M., Roza C., De Felipe C., Hunt S.P., Cervero F. Role of central and peripheral tachykinin NK1 receptors in capsaicin-induced pain and hyperalgesia in mice. Pain. 90:2001;97-103.
43. Davis K.D., Meyer R.A., Turnquist J.L., Filloon T.G., Pappagallo M., Campbell J.N. Cutaneous pretreatment with the capsaicin analog NE-21610 prevents the pain to a burn and subsequent hyperalgesia. Pain. 62:1995;373-378.
44. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway [see comments]. Nature. 389:1997;816-824.
45. Nolano M., Simone D.A., Wendelschafer-Crabb G., Johnson T., Hazen E., Kennedy W.R. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain. 81:1999;135-145.
46. Myers A.C., Kajekar R., Undem B.J. Allergic inflammation-induced neuropeptide production in rapidly adapting afferent nerves in guinea pig airways. Am J Physiol Lung Cell Mol Physiol. 282:2002;L775-L781.
47. Kagaya M., Lamb J., Robbins J., Page C.P., Spina D. Characterization of the anandamide induced depolarization of guinea-pig isolated vagus nerve. Br J Pharmacol. 137:2002;39-48.
48. Guo A., Vulchanova L., Wang J., Li X., Elde R. Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur J Neurosci. 11:1999;946-958.
49. Lin Q., Zou X., Willis W.D. Ad and C primary afferents convey dorsal root reflexes after intradermal injection of capsaicin in rats. J Neurophysiol. 84:2000;2695-2698.
50. Eisenach J.C., Hood D.D., Curry R. Relative potency of epidural to intrathecal clonidine differs between acute thermal pain and capsaicin-induced allodynia. Pain. 84:2000;57-64.
51. Eisenach J.C., Hood D.D., Curry R. Intrathecal, but not intravenous, clonidine reduces experimental thermal or capsaicin-induced pain and hyperalgesia in normal volunteers. Anesth Analg. 87:1998;591-596.
52. Kingery W.S. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain. 73:1997;123-139.
53. Kost R.G., Straus S.E. Postherpetic neuralgia-pathogenesis, treatment, and prevention. N Engl J Med. 335:1996;32-42.
54. Langmayr J.J., Obwegeser A.A., Schwarz A.B., Laimer I., Ulmer H., Ortler M. Intrathecal steroids to reduce pain after lumbar disc surgery: a double- blind, placebo-controlled prospective study. Pain. 62:1995;357-361.
55. Kotani N., Kushikata T., Hashimoto H., Kimura F., Muraoka M., Yodono M., Asai M., Matsuki A. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med. 343:2000;1514-1519.
56. Safieh-Garabedian B., Poole S., Allchorne A., Winter J., Woolf C.J. Contribution of interleukin-1 beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br J Pharmacol. 115:1995;1265-1275.
57. Ferreira S.H., Cunha F.Q., Lorenzetti B.B., Michelin M.A., Perretti M., Flower R.J., Poole S. Role of lipocortin-1 in the anti-hyperalgesic actions of dexamethasone. Br J Pharmacol. 121:1997;883-888.
58. Safieh-Garabedian B., Kanaan S.A., Haddad J.J., Jaoude P.A., Jabbur S.J., Saade N.E. Involvement of interleukin-1 beta, nerve growth factor and prostaglandin E2 in endotoxin-induced localized inflammatory hyperalgesia. Br J Pharmacol. 121:1997;1619-1626.
59. Safieh-Garabedian B., Dardenne M., Pleau J.M., Saade N.E. Potent analgesic and anti-inflammatory actions of a novel thymulin-related peptide in the rat. Br J Pharmacol. 136:2002;947-955.
60. Kingery W.S., Agashe G.S., Sawamura S., Davies M.F., Clark J.D., Maze M. Glucocorticoid inhibition of neuropathic hyperalgesia and spinal Fos expression. Anesth Analg. 92:2001;476-482.
61. Kingery W.S., Guo T., Agashe G.S., Davies M.F., Clark J.D., Maze M. Glucocorticoid inhibition of neuropathic limb edema and cutaneous neurogenic extravasation. Brain Res. 913:2001;140-148.
62. Johansson A., Hao J., Sjolund B. Local corticosteroid application blocks transmission in normal nociceptive C-fibres. Acta Anaesthesiol Scand. 34:1990;335-338.
63. Pedersen J.L., Moiniche S., Kehlet H. Topical glucocorticoid has no antinociceptive or anti-inflammatory effect in thermal injury. Br J Anaesth. 72:1994;379-382.
64. Werner M.U., Lassen B., Pedersen J.L., Kehlet H. Local cooling does not prevent hyperalgesia following burn injury in humans. Pain. 98:2002;297-303.
65. Werner M.U., Lassen B., Kehlet H. Analgesic effects of dexamethasone in burn injury. Reg Anesth Pain Med. 27:2002;254-260.
66. Holte K., Werner M.U., Lacouture P.G., Kehlet H. Dexamethasone prolongs local analgesia after subcutaneous infiltration of bupivacaine microcapsules in human volunteers. Anesthesiology. 96:2002;1331-1335.
67. Vignola A.M., Chanez P., Bonsignore G., Godard P., Bousquet J. Structural consequences of airway inflammation in asthma. J Allergy Clin Immunol. 105:2000;S514-S517.
68. Fredberg J.J. Frozen objects: small airways, big breaths, and asthma. J Allergy Clin Immunol. 106:2000;615-624.
69. Holgate S.T., Lackie P., Wilson S., Roche W., Davies D. Bronchial epithelium as a key regulator of airway allergen sensitization and remodeling in asthma. Am J Respir Crit Care Med. 162:2000;S113-S117.
70. Romagnani S. The role of lymphocytes in allergic disease. J Allergy Clin Immunol. 105:2000;399-408.
71. Gleich G.J. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol. 105:2000;651-663.
72. Cockcroft D.W., Killian D.N., Mellon J.J., Hargreave F.E. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy. 7:1977;235-243.
73. De Meer G., Heederik D., Postma D.S. Bronchial responsiveness to adenosine 5′-monophosphate (AMP) and methacholine differ in their relationship with airway allergy and baseline FEV(1). Am J Respir Crit Care Med. 165:2002;327-331.
74. Berman A.R., Togias A.G., Skloot G., Proud D. Allergen-induced hyperresponsiveness to bradykinin is more pronounced than that to methacholine. J Appl Physiol. 78:1995;1844-1852.
75. Sont J.K., Willems L.N., Bel E.H., van Krieken J.H., Vandenbroucke J.P., Sterk P.J. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med. 159:1999;1043-1051.
76. Sestini P., Refini R.M., Pieroni M.G., Vaghi A., Robuschi M., Bianco S. Protective effect of inhaled lysine acetylsalicylate on allergen-induced early and late asthmatic reactions. J Allergy Clin Immunol. 100:1997;71-77.
77. Sestini P., Refini R.M., Pieroni M.G., Vaghi A., Robuschi M., Bianco S. Different effects of inhaled aspirin like drugs on allergen-induced early and late asthmatic responses. Am J Respir Crit Care Med. 159:1999;1228-1233.
78. Murray J.J., Tonnel A.B., Brash A.R., Roberts L.J., Gosset P., Workman R., Capron A., Oates J.A. Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med. 315:1986;800-804.
79. Liu M.C., Bleecker E.R., Lichtenstein L.M., Kagey-Sobotka A., Niv Y., McLemore T.L., Permutt S., Proud D., Hubbard W.C. Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am Rev Respir Dis. 142:1990;126-132.
80. Dworski R., Fitzgerald G.A., Oates J.A., Sheller J.R. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med. 149:1994;953-959.
81. Fairfax A.J., Hanson J.M., Morley J. The late reaction following bronchial provocation with house dust mite allergen. Dependence on arachidonic acid metabolism. Clin Exp Immunol. 52:1983;393-398.
82. Joubert J.R., Shephard E., Mouton W., Van Zyl L., Viljoen I. Non-steroid anti-inflammatory drugs in asthma: dangerous or useful therapy? Allergy. 40:1985;202-207.
83. Kirby J.G., Hargreave F.E., Cockcroft D.W., O'Byrne P.M. Effect of indomethacin on allergen-induced asthmatic responses. J Appl Physiol. 66:1989;578-583.
84. Hardy C.C., Robinson C., Tattersfield A.E., Holgate S.T. The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men. N Engl J Med. 311:1984;209-213.
85. Fish J.E., Jameson L.S., Albright A., Norman P.S. Modulation of the bronchomotor effects of chemical mediators by prostaglandin F2 alpha in asthmatic subjects. Am Rev Respir Dis. 130:1984;571-574.
86. Saroea H.G., Inman M.D., O'Byrne P.M. U46619-induced bronchoconstriction in asthmatic subjects is mediated by acetylcholine release. Am J Respir Crit Care Med. 151:1995;321-324.
87. Heaton R.W., Henderson A.F., Dunlop L.S., Costello J.F. The influence of pretreatment with prostaglandin F2 alpha on bronchial sensitivity to inhaled histamine and methacholine in normal subjects. Br J Dis Chest. 78:1984;168-173.
88. Fuller R.W., Dixon C.M., Dollery C.T., Barnes P.J. Prostaglandin D2 potentiates airway responsiveness to histamine and methacholine. Am Rev Respir Dis. 133:1986;252-254.
89. Crimi N., Polosa R., Magri S., Prosperini G., Milazzo V.L., Santonocito G., Mistretta A. Inhaled lysine acetylsalicylate (L-ASA) attenuates the bronchoconstrictor response to adenosine 5′-monophosphate (AMP) in asthmatic subjects. Eur Respir J. 8:1995;905-912.
90. Polosa R., Milazzo V.L., Magri S., Pagano C., Paolino G., Santonocito G., Prosperini G., Crimi N. Activity of inhaled lysine acetylsalicylate (L-ASA) on bradykinin- induced bronchoconstriction in asthmatics: evidence of contribution of prostaglandins. Eur Respir J. 10:1997;866-871.
91. Field P.I., Simmul R., Bell S.C., Allen D.H., Berend N. Evidence for opioid modulation and generation of prostaglandins in sulphur dioxide (SO)2-induced bronchoconstriction. Thorax. 51:1996;159-163.
92. Shimizu T., Mochizuki H., Shigeta M., Morikawa A. Effect of inhaled indomethacin on exercise-induced bronchoconstriction in children with asthma. Am J Respir Crit Care Med. 155:1997;170-173.
93. Bianco S., Vaghi A., Pieroni M.G., Robuschi M., Refini R.M., Sestini P. Protective activity of inhaled nonsteroidal antiinflammatory drugs on bronchial responsiveness to ultrasonically nebulized water. J Allergy Clin Immunol. 90:1992;833-839.
94. Margolskee D.J., Bigby B.G., Boushey H.A. Indomethacin blocks airway tolerance to repetitive exercise but not to eucapnic hyperpnea in asthmatic subjects. Am Rev Respir Dis. 137:1988;842-846.
95. Matsuoka T., Hirata M., Tanaka H., Takahashi Y., Murata T., Kabashima K., Sugimoto Y., Kobayashi T., Ushikubi F., Aze Y., Eguchi N., Urade Y., Yoshida N., Kimura K., Mizoguchi A., Honda Y., Nagai H., Narumiya S. Prostaglandin D2 as a mediator of allergic asthma. Science. 287:2000;2013-2017.
96. Choudry N.B., Fuller R.W., Pride N.B. Sensitivity of the human cough reflex: effect of inflammatory mediators prostaglandin E2, bradykinin, and histamine. Am Rev Respir Dis. 140:1989;137-141.
97. Betz M., Fox B.S. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol. 146:1991;108-113.
98. Snijdewint F.G., Kalinski P., Wierenga E.A., Bos J.D., Kapsenberg M.L. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol. 150:1993;5321-5329.
99. van der Pouw Kraan T.C., Boeije L.C., Smeenk R.J., Wijdenes J., Aarden L.A. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med. 181:1995;775-779.
100. Hartert T.V., Dworski R.T., Mellen B.G., Oates J.A., Murray J.J., Sheller J.R. Prostaglandin E(2) decreases allergen-stimulated release of prostaglandin D(2) in airways of subjects with asthma. Am J Respir Crit Care Med. 162:2000;637-640.
101. Knight D.A., Stewart G.A., Thompson P.J. Prostaglandin E2, but not prostacyclin inhibits histamine-induced contraction of human bronchial smooth muscle. Eur J Pharmacol. 272:1995;13-19.
102. Johnson P.R., Armour C.L., Carey D., Black J.L. Heparin and PGE2 inhibit DNA synthesis in human airway smooth muscle cells in culture. Am J Physiol. 269:1995;L514-L519.
103. Pavord I.D., Wong C.S., Williams J., Tattersfield A.E. Effect of inhaled prostaglandin E2 on allergen-induced asthma. Am Rev Respir Dis. 148:1993;87-90.
104. Gauvreau G.M., Watson R.M., O'Byrne P.M. Protective effects of inhaled PGE2 on allergen-induced airway responses and airway inflammation. Am J Respir Crit Care Med. 159:1999;31-36.
105. Noguchi K., Iwasaki K., Endo H., Kondo H., Shitashige M., Ishikawa I. Prostaglandins E2 and I2 downregulate tumor necrosis factor alpha-induced intercellular adhesion molecule-1 expression in human oral gingival epithelial cells. Oral Microbiol Immunol. 15:2000;299-304.
106. Peebles R.S. Jr, Dworski R., Collins R.D., Jarzecka K., Mitchell D.B., Graham B.S., Sheller J.R. Cyclooxygenase inhibition increases interleukin 5 and interleukin 13 production and airway hyperresponsiveness in allergic mice. Am J Respir Crit Care Med. 162:2000;676-681.
107. Peebles R.S. Jr, Hashimoto K., Morrow J.D., Dworski R., Collins R.D., Hashimoto Y., Christman J.W., Kang K.H., Jarzecka K., Furlong J., Mitchell D.B., Talati M., Graham B.S., Sheller J.R. Selective cyclooxygenase-1 and -2 inhibitors each increase allergic inflammation and airway hyperresponsiveness in mice. Am J Respir Crit Care Med. 165:2002;1154-1160.
108. Gavett S.H., Madison S.L., Chulada P.C., Scarborough P.E., Qu W., Boyle J.E., Tiano H.F., Lee C.A., Langenbach R., Roggli V.L., Zeldin D.C. Allergic lung responses are increased in prostaglandin H synthase-deficient mice. J Clin Invest. 104:1999;721-732.
109. Irvin C.G., Tu Y.P., Sheller J.R., Funk C.D. 5-Lipoxygennase products are necessary for ovalbumin-induced airway responsiveness in mice. Am J Physiol. 272:1997;L1053-L1058.
110. Szczeklik A., Sladek K., Dworski R., Nizankowska E., Soja J., Sheller J., Oates J. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am J Respir Crit Care Med. 154:1996;1608-1614.
111. Sheller J.R., Mitchell D., Meyrick B., Oates J., Breyer R. EP(2) receptor mediates bronchodilation by PGE(2) in mice. J Appl Physiol. 88:2000;2214-2218.
112. Tavakoli S., Cowan M.J., Benfield T., Logun C., Shelhamer J.H. Prostaglandin E(2)-induced interleukin-6 release by a human airway epithelial cell line. Am J Physiol Lung Cell Mol Physiol. 280:2001;L127-L133.
113. Fuller R.W., Karlsson J.A., Choudry N.B., Pride N.B. Effect of inhaled and systemic opiates on responses to inhaled capsaicin in humans. J Appl Physiol. 65:1988;1125-1130.
114. Popa V. Codeine-induced bronchoconstriction and putative bronchial opiate receptors in asthmatic subjects. Pulm Pharmacol. 7:1994;333-341.
115. Eschenbacher W.L., Bethel R.A., Boushey H.A., Sheppard D. Morphine sulfate inhibits bronchoconstriction in subjects with mild asthma whose responses are inhibited by atropine. Am Rev Respir Dis. 130:1984;363-367.
116. Garland L. The effect of a peripherally-acting opioid on sensory nerve function. Pulm Pharmacol. 8:1995;231-236.
117. Pavord I., Hall I., Wahedna I., Cooper S., Tattersfield A. Effect of 443c81, an inhaled mu-opioid receptor agonist in asthma. Clin Exp Allergy. 24:1994;144-148.
118. Sanico A.M., Philip G., Lai G.K., Togias A. Hyperosmolar saline induces reflex nasal secretions, evincing neural hyperresponsiveness in allergic rhinitis. J Appl Physiol. 86:1999;1202-1210.
119. Caire N., Cartier A., Ghezzo H., L'Archeveque J., Malo J.L. Inhaled lignocaine does not alter bronchial hyperresponsiveness to hyperventilation of dry cold air in asthmatic subjects. Clin Exp Allergy. 19:1989;65-70.
120. Sheppard D., Rizk N.W., Boushey H.A., Bethel R.A. Mechanism of cough and bronchoconstriction induced by distilled water aerosol. Am Rev Respir Dis. 127:1983;691-694.
121. Griffin M.P., McFadden E.R. Jr, Ingram R.H. Jr, Pardee S. Controlled-analysis of the effects of inhaled lignocaine in exercise-induced asthma. Thorax. 37:1982;741-745.
122. Chen W.Y., Chai H. Effects of inhaled lidocaine on exercise-induced asthma. Respiration. 51:1987;91-97.
123. Tullett W.M., Patel K.R., Berkin K.E., Kerr J.W. Effect of lignocaine, sodium cromoglycate, and ipratropium bromide in exercise-induced asthma. Thorax. 37:1982;737-740.
124. Groeben H., Schwalen A., Irsfeld S., Stieglitz S., Lipfert P., Hopf H.B. Intravenous lidocaine and bupivacaine dose-dependently attenuate bronchial hyperreactivity in awake volunteers. Anesthesiology. 84:1996;533-539.
125. Groeben H., Silvanus M.T., Beste M., Peters J. Both intravenous and inhaled lidocaine attenuate reflex bronchoconstriction but at different plasma concentrations. Am J Respir Crit Care Med. 159:1999;530-535.
126. Groeben H., Grosswendt T., Silvanus M., Beste M., Peters J. Lidocaine inhalation for local anaesthesia and attenuation of bronchial hyper-reactivity with least airway irritation. Effect of three different dose regimens. Eur J Anaesthesiol. 17:2000;672-679.
127. Shono S., Higa K., Harasawa I., Sugano H., Dan K. Disappearance of wheezing during epidural lidocaine anesthesia in a patient with bronchial asthma. Reg Anesth Pain Med. 24:1999;463-466.
128. Hunt L.W., Swedlund H.A., Gleich G.J. Effect of nebulized lidocaine on severe glucocorticoid-dependent asthma. Mayo Clin Proc. 71:1996;361-368.
129. Makker H.K., Holgate S.T. The contribution of neurogenic reflexes to hypertonic saline- induced bronchoconstriction in asthma. J Allergy Clin Immunol. 92:1993;82-88.
130. Enright P.L., McNally J.F., Souhrada J.F. Effect of lidocaine on the ventilatory and airway responses to exercise in asthmatics. Am Rev Respir Dis. 122:1980;823-828.
131. Harrison T.W., Tattersfield A.E. Effect of single doses of inhaled lignocaine on FEV1 and bronchial reactivity in asthma. Respir Med. 92:1998;1359-1363.
132. Fish J.E., Peterman V.I. Effects of inhaled lidocaine on airway function in asthmatic subjects. Respiration. 37:1979;201-207.
133. McAlpine L.G., Thomson N.C. Lidocaine-induced bronchoconstriction in asthmatic patients. Relation to histamine airway responsiveness and effect of preservative [see comments]. Chest. 96:1989;1012-1015.
134. Midgren B., Hansson L., Karlsson J.A., Simonsson B.G., Persson C.G. Capsaicin-induced cough in humans. Am Rev Respir Dis. 146:1992;347-351.
135. Millqvist E. Cough provocation with capsaicin is an objective way to test sensory hyperreactivity in patients with asthma-like symptoms. Allergy. 55:2000;546-550.
136. Andersson R.G., Fugner A., Lindgren B.R., Muacevic G. Inhibitory effects of clonidine on bronchospasm induced in guinea-pigs by vagal stimulation or antigen challenge. Eur J Pharmacol. 123:1986;181-185.
137. Grundstrom N., Andersson R.G. In vivo demonstration of alpha-2-adrenoceptor-mediated inhibition of the excitatory non-cholinergic neurotransmission in guinea pig airways. Naunyn Schmiedebergs Arch Pharmacol. 328:1985;236-240.
138. Grundstrom N., Andersson R.G., Wikberg J.E. Prejunctional alpha 2 adrenoceptors inhibit contraction of tracheal smooth muscle by inhibiting cholinergic neurotransmission. Life Sci. 28:1981;2981-2986.
139. Lindgren B.R., Ekstrom T., Andersson R.G. The effect of inhaled clonidine in patients with asthma. Am Rev Respir Dis. 134:1986;266-269.
140. O' Connell F., Thomas V.E., Fuller R.W., Pride N.B., Karlsson J.A. Effect of clonidine on induced cough and bronchoconstriction in guinea pigs and healthy humans. J Appl Physiol. 76:1994;1082-1087.
141. Foxworth J.W., Reisz G.R., Pyszczynski D.R., Knudson S.M. Oral clonidine in patients with asthma: no significant effect on airway reactivity. Eur J Clin Pharmacol. 48:1995;19-22.
142. Scott G.C., Chu C.S., Braun S.R. Transdermal delivery of the alpha 2-agonist clonidine does not alter airways responses to inhaled histamine or methacholine. Chest. 100:1991;1035-1038.
143. Dinh Xuan A.T., Matran R., Regnard J., Vitou P., Advenier C., Lockhart A. Comparative effects of rilmenidine and clonidine on bronchial responses to histamine in asthmatic subjects. Br J Clin Pharmacol. 26:1988;703-708.
144. Dinh Xuan A.T., Regnard J., Matran R., Mantrand P., Advenier C., Lockhart A. Effects of clonidine on bronchial responses to histamine in normal and asthmatic subjects. Eur Respir J. 1:1988;345-350.
145. Szallasi A., Blumberg P.M. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev. 51:1999;159-211.
146. Spina D., McKenniff M.G., Coyle A.J., Seeds E.A., Tramontana M., Perretti F., Manzini S., Page C.P. Effect of capsaicin on PAF-induced bronchial hyperresponsiveness and pulmonary cell accumulation in the rabbit. Br J Pharmacol. 103:1991;1268-1274.
147. Riccio M.M., Matsumoto T., Adcock J.J., Douglas G.J., Spina D., Page C.P. The effect of 15-HPETE on airway responsiveness and pulmonary cell recruitment in rabbits. Br J Pharmacol. 122:1997;249-256.
148. Riccio M.M., Manzini S., Page C.P. The effect of neonatal capsaicin on the development of bronchial hyperresponsiveness in allergic rabbits. Eur J Pharmacol. 232:1993;89-97.
149. Herd C.M., Gozzard N., Page C.P. Capsaicin pretreatment prevents the development of antigen induced airway hyperresponsiveness in neonatally immunized rabbits. Eur J Pharmacol. 282:1995;111-119.
150. Kraneveld A.D., James D.E., De Vries K., Nijkamp F.P. Excitatory non-adrenergic-non-cholinergic neuropeptides: key players in asthma. Eur J Pharmacol. 405:2000;113-129.
151. Schmidt D., Jorres R.A., Rabe K.F., Magnussen H. Reproducibility of airway response to inhaled bradykinin and effect of the neurokinin receptor antagonist FK-224 in asthmatic subjects. Eur J Clin Pharmacol. 50:1996;269-273.
152. Ichinose M., Miura M., Yamauchi H., Kageyama N., Tomaki M., Oyake T., Ohuchi Y., Hida W., Miki H., Tamura G., Shirato K. A neurokinin 1-receptor antagonist improves exercise-induced airway narrowing in asthmatic patients. Am J Respir Crit Care Med. 153:1996;936-941.
153. Fahy J.V., Wong H.H., Geppetti P., Reis J.M., Harris S.C., Maclean D.B., Nadel J.A., Boushey H.A. Effect of an NK1 receptor antagonist (CP-99,994) on hypertonic saline-induced bronchoconstriction and cough in male asthmatic subjects. Am J Respir Crit Care Med. 152:1995;879-884.
154. Kraan J., Vink-Klooster H., Postma D.S. The NK-2 receptor antagonist SR 48968C does not improve adenosine hyperresponsiveness and airway obstruction in allergic asthma. Clin Exp Allergy. 31:2001;274-278.
155. Woisin F.E., Matsumoto T., Douglas G.J., Paul W., Whalley E.T., Page C.P. Effect of antagonists for NK2 and B2 receptors on antigen-induced airway responses in allergic rabbits. Pulm Pharmacol Ther. 13:2000;13-24.
156. Tominaga M., Caterina M.J., Malmberg A.B., Rosen T.A., Gilbert H., Skinner K., Raumann B.E., Basbaum A.I., Julius D. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron. 21:1998;531-543.
157. Hay D.W., Giardina G.A., Griswold D.E., Underwood D.C., Kotzer C.J., Bush B., Potts W., Sandhu P., Lundberg D., Foley J.J., Schmidt D.B., Martin L.D., Kilian D., Legos J.J., Barone F.C., Luttmann M.A., Grugni M., Raveglia L.F., Sarau H.M. Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs. J Pharmacol Exp Ther. 300:2002;314-323.
158. Daoui S., Cognon C., Naline E., Emonds-Alt X., Advenier C. Involvement of tachykinin NK3 receptors in citric acid-induced cough and bronchial responses in guinea pigs. Am J Respir Crit Care Med. 158:1998;42-48.
159. Konig P. The effects of cromolyn sodium and nedocromil sodium in early asthma prevention. J Allergy Clin Immunol. 105:2000;S575-S581.
160. Stokes T.C., Morley J. Prospects for an oral Intal. Br J Dis Chest. 75:1981;1-14.
161. Mann J.S., Clement P., Sheridan A.Q., Soryal I., Fairfax A.J., Holgate S.T. Inhaled lodoxamide tromethamine in the treatment of perennial asthma: a double-blind placebo-controlled study. J Allergy Clin Immunol. 76:1985;83-90.
162. Dixon M., Jackson D.M., Richards I.M. The action of sodium cromoglycate on 'C' fibre endings in the dog lung. Br J Pharmacol. 70:1980;11-13.
163. Jackson D.M., Pollard C.E., Roberts S.M. The effect of nedocromil sodium on the isolated rabbit vagus nerve. Eur J Pharmacol. 221:1992;175-177.
164. Norris A.A., Alton E.W. Chloride transport and the action of sodium cromoglycate and nedocromil sodium in asthma. Clin Exp Allergy. 26:1996;250-253.
165. Ahluwalia P., McGill J.I., Church M.K. Nedocromil sodium inhibits histamine-induced itch and flare in human skin. Br J Pharmacol. 132:2001;613-616.
166. Crimi N., Palermo F., Oliveri R., Vancheri C., Polosa R., Palermo B., Maccarrone C., Mistretta A. Comparative study of the effects of nedocromil sodium (4 mg) and sodium cromoglycate (10 mg) on adenosine-induced bronchoconstriction in asthmatic subjects. Clin Allergy. 18:1988;367-374.
167. Richards R., Phillips G.D., Holgate S.T. Nedocromil sodium is more potent than sodium cromoglycate against AMP-induced bronchoconstriction in atopic asthmatic subjects. Clin Exp Allergy. 19:1989;285-291.
168. Crimi N., Palermo F., Oliveri R., Palermo B., Vancheri C., Polosa R., Mistretta A. Effect of nedocromil on bronchospasm induced by inhalation of substance P in asthmatic subjects. Clin Allergy. 18:1988;375-382.
169. Joos G.F., Pauwels R.A., Van der Straeten M.E. The effect of
170. Fuller R.W., Dixon C.M., Cuss F.M., Barnes P.J. Bradykinin-induced bronchoconstriction in humans. Mode of action. Am Rev Respir Dis. 135:1987;176-180.
171. Dixon C.M., Barnes P.J. Bradykinin-induced bronchoconstriction: inhibition by nedocromil sodium and sodium cromoglycate. Br J Clin Pharmacol. 27:1989;831-836.
172. Harries M.G., Parkes P.E., Lessof M.H., Orr T.S. Role of bronchial irritant receptors in asthma. Lancet. 1:1981;5-7.
173. Altounyan R.E., Lee T.B., Rocchiccioli M.S., Shaw C.L. A comparison of the inhibitory effects of nedocromil sodium and SCG on adenosine monophosphate-induced bronchoconstriction in atopic subjects. Eur J Respir Dis. 69:(Suppl 147):1986;277-279.
174. Dixon C.M., Ind P.W. Inhaled sodium metabisulphite induced bronchoconstriction: inhibition by nedocromil sodium and sodium cromoglycate. Br J Clin Pharmacol. 30:1990;371-376.
175. Konig P., Hordvik N.L., Kreutz C. The preventive effect and duration of action of nedocromil sodium and cromolyn sodium on exercise-induced asthma (EIA) in adults. J Allergy Clin Immunol. 79:1987;64-68.
176. Boulet L.P., Turcotte H., Tennina S. Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges. J Allergy Clin Immunol. 83:1989;882-887.
177. Anderson S.D., Rodwell L.T., Daviskas E., Spring J.F., du T J. The protective effect of nedocromil sodium and other drugs on airway narrowing provoked by hyperosmolar stimuli: a role for the airway epithelium? J Allergy Clin Immunol. 98:1996;S124-S134.
178. Tranfa C.M., Vatrella A., Parrella R., Bariffi F. Effect of ipratropium bromide and/or sodium cromoglycate pretreatment on water-induced bronchoconstriction in asthma. Eur Respir J. 8:1995;600-604.
179. Juniper E.F., Kline P.A., Morris M.M., Hargreave F.E. Airway constriction by isocapnic hyperventilation of cold, dry air: comparison of magnitude and duration of protection by nedocromil sodium and sodium cromoglycate. Clin Allergy. 17:1987;523-528.
180. Jain N.K., Kulkarni S.K., Singh A. Role of cysteinyl leukotrienes in nociceptive and inflammatory conditions in experimental animals. Eur J Pharmacol. 423:2001;85-92.
181. Cordoba-Rodriguez R., Moore K.A., Kao J.P., Weinreich D. Calcium regulation of a slow post-spike hyperpolarization in vagal afferent neurons. Proc Natl Acad Sci USA. 96:1999;7650-7657.
182. Sheftell F., Rapoport A., Weeks R., Walker B., Gammerman I., Baskin S. Montelukast in the prophylaxis of migraine: a potential role for leukotriene modifiers. Headache. 40:2000;158-163.
183. Van Schoor J., Joos G.F., Kips J.C., Drajesk J.F., Carpentier P.J., Pauwels R.A. The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects. Am J Respir Crit Care Med. 155:1997;875-880.
184. Rorke S., Jennison S., Jeffs J.A., Sampson A.P., Arshad H., Holgate S.T. Role of cysteinyl leukotrienes in adenosine 5′-monophosphate induced bronchoconstriction in asthma. Thorax. 57:2002;323-327.
185. Lazarus S.C., Wong H.H., Watts M.J., Boushey H.A., Lavins B.J., Minkwitz M.C. The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med. 156:1997;1725-1730.
186. Reiss T.F., Hill J.B., Harman E., Zhang J., Tanaka W.K., Bronsky E., Guerreiro D., Hendeles L. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax. 52:1997;1030-1035.
187. Dekhuijzen P.N., Bootsma G.P., Wielders P.L., van den Berg L.R., Festen J., van Herwaarden C.L. Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids. Eur Respir J. 10:1997;2749-2753.
188. Fischer A.R., Rosenberg M.A., Roth M., Loper M., Jungerwirth S., Israel E. Effect of a novel 5-lipoxygenase activating protein inhibitor, BAYx 1005, on asthma induced by cold dry air. Thorax. 52:1997;1074-1077.
189. Jacoby D.B., Costello R.M., Fryer A.D. Eosinophil recruitment to the airway nerves. J Allergy Clin Immunol. 107:2001;211-218.
190. Said S.I. Glutamate receptors and asthmatic airway disease. Trends Pharmacol Sci. 20:1999;132-134.
191. Said S.I., Dey R.D., Dickman K. Glutamate signalling in the lung. Trends Pharmacol Sci. 22:2001;344-345.
192. Bacci E., Di Franco A., Bartoli M.L., Carnevali S., Cianchetti S., Dente F.L., Giannini D., Vagaggini B., Ruocco L., Paggiaro P.L. Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma. Eur Respir J. 20:2002;66-72.
193. Faul J.L., Demers E.A., Burke C.M., Poulter L.W. Alterations in airway inflammation and lung function during corticosteroid therapy for atopic asthma. Chest. 121:2002;1414-1420.
194. Meijer R.J., Kerstjens H.A., Arends L.R., Kauffman H.F., Koeter G.H., Postma D.S. Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma. Thorax. 54:1999;894-899.
195. Jonasson G., Carlsen K.H., Hultquist C. Low-dose budesonide improves exercise-induced bronchospasm in school children. Pediatr Allergy Immunol. 11:2000;120-125.
196. Groot C.A., Lammers J.W., Molema J., Festen J., van Herwaarden C.L. Effect of inhaled beclomethasone and nedocromil sodium on bronchial hyperresponsiveness to histamine and distilled water. Eur Respir J. 5:1992;1075-1082.
197. Nielsen K.G., Bisgaard H. The effect of inhaled budesonide on symptoms, lung function, and cold air and methacholine responsiveness in 2- to 5-year-old asthmatic children. Am J Respir Crit Care Med. 162:2000;1500-1506.
198. Reynolds C.J., Togias A., Proud D. Airways hyper-responsiveness to bradykinin and methacholine: effects of inhaled fluticasone. Clin Exp Allergy. 32:2002;1174-1179.
199. Van Schoor J., Joos G.F., Pauwels R.A. Effect of inhaled fluticasone on bronchial responsiveness to neurokinin A in asthma. Eur Respir J. 19:2002;997-1002.
200. Ketchell R.I., Jensen M.W., Lumley P., Allenby M., Costello J.F., O'Connor B.J. Rapid effect of a single dose of inhaled fluticasone propionate on airway responsiveness to AMP in mild asthma. Am J Respir Crit Care Med. 163:2001;A420.
201. Parameswaran K., Inman M.D., Watson R.M., Morris M.M., Efthimiadis A., Ventresca P.G., Lam R., O'Byrne P.M., Hargreave F.E. Protective effects of fluticasone on allergen-induced airway responses and sputum inflammatory markers. Can Respir J. 7:2000;313-319.
202. Kumar S.D., Brieva J.L., Danta I., Wanner A. Transient effect of inhaled fluticasone on airway mucosal blood flow in subjects with and without asthma. Am J Respir Crit Care Med. 161:2000;918-921.
203. Bonham A.C., Kott K.S., Ravi K., Kappagoda C.T., Joad J.P. Substance P contributes to rapidly adapting receptor responses to pulmonary venous congestion in rabbits. J Physiol Lond. 493:1996;229-238.
204. Spina D., Page C.P. Pharmacology of airway irritability. Curr Opin Pharmacol. 2:2002;264-272.